Zydus to settle Mirabegron patent litigation with Astellas by paying $120 million
The agreement concludes all litigation between Astellas and the two companies relating to Myrbetriq and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the U.S.
The agreement concludes all litigation between Astellas and the two companies relating to Myrbetriq and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the U.S.
What's Your Reaction?
